Research programme: allogeneic T-cell therapies - Kite Pharma
Latest Information Update: 02 Aug 2016
At a glance
- Originator Kite Pharma
- Class Stem cell therapies
- Mechanism of Action Cell replacements; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer